DERM - Dermira, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Dermira, Inc.

275 Middlefield Road
Suite 150
Menlo Park, CA 94025
United States
650-421-7200
http://www.dermira.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees333

Key Executives

NameTitlePayExercisedYear Born
Mr. Thomas G. WiggansCo-Founder, CEO & Chairman898.83k104.94k1952
Mr. Luis C. PeñaCo-Founder & Chief Devel. Officer564.65kN/A1963
Mr. Andrew L. GuggenhimeChief Financial Officer561.56kN/A1968
Mr. Christopher HoranChief Technical Operations Officer613.69kN/A1967
Ms. Lori Lyons-WilliamsChief Commercial Officer654.01kN/A1977
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Dermira, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older. It also develops lebrikizumab, a novel injectable humanized monoclonal antibody targeting interleukin 13 that is in Phase IIb clinical trial for the treatment of moderate-to-severe atopic dermatitis; and early-stage research and development programs in other areas of dermatology. Dermira, Inc. has a right of first negotiation agreement with Maruho Co., Ltd. to develop and commercialize glycopyrronium tosylate for the treatment of hyperhidrosis in Japan; an agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. to develop and commercialize lebrikizumab; and a development and commercialization agreement with UCB Pharma S.A. to develop Cimzia for the treatment of psoriasis. The company was formerly known as Skintelligence, Inc. and changed its name to Dermira, Inc. in September 2011. Dermira, Inc. was founded in 2010 and is headquartered in Menlo Park, California.

Corporate Governance

Dermira, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 9. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.